ASCO GI 2020: Expert Thoughts on Key Studies
  • CME

January 23-25, 2020; San Francisco, California
Read the experts’ thoughts on how data presented at the recent ASCO GI meeting in San Francisco will affect their practice.
Axel Grothey Headshot
Axel Grothey, MD
R. Kate Kelley, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: February 26, 2020 Expiration: February 25, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with gastrointestinal cancers
  • Identify subpopulations of patients with cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Evaluate the unique mechanisms of action of promising investigational agents being studied for the treatment of gastrointestinal cancers
  • Discuss new data on novel agents and therapeutic approaches for patients with gastrointestinal cancers
  • Consider emerging clinical data on novel agents and therapeutic strategies that have the potential to improve the outcomes for patients with gastrointestinal cancers

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Merck Sharp & Dohme Corp

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Axel Grothey, MD

Director of GI Cancer Research
West Cancer Center and Research Institute
Germantown, Tennessee

Axel Grothey, MD, has disclosed that his institution received fees for his consulting activities from Array/Pfizer, Bayer, Boston Biomedicals, Bristol-Myers Squibb, Genentech, and Roche.
R. Kate Kelley, MD

Associate Professor
Division of Hematology and Oncology
University of California, San Francisco
San Francisco, California

R. Kate Kelley, MD, has disclosed that she has received consulting fees from Genentech/Roche, Gilead Sciences, and Ipsen; has performed consulting under institutional agreements with Agios, AstraZeneca, Bayer, and Bristol-Myers Squibb (without personal compensation); and has received funds for research support (paid to her institution) from Agios, AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Lilly, MedImmune, Merck, Novartis, Partner Therapeutics, QED, and Taiho.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with gastrointestinal cancers.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with gastrointestinal cancers.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 26, 2020, through February 25, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From Clinical Care Options (CCO), expert commentary by Dr Richard Finn on the use of atezolizumab plus bevacizumab for advanced HCC

Richard Finn, MD Released: September 15, 2020

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC

person default Lipika Goyal Goyal, MD, MPhil Amit G. Singal, MD, MS Released: September 14, 2020

In slides from Clinical Care Options (CCO), experts provide multidisciplinary insights on the optimal use of immune checkpoint inhibitors for HCC

person default Lipika Goyal Goyal, MD, MPhil Amit G. Singal, MD, MS Released: September 9, 2020

Experts discuss key data in GI and lung malignancies from ASCO 2020 and optimization of therapeutic benefit through management of cancer cachexia syndrome, from CCO

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?